Biomarin Historical Income Statement
BMRN Stock | USD 90.07 0.40 0.44% |
Historical analysis of Biomarin Pharmaceutical income statement accounts such as Interest Expense of 18 M, Selling General Administrative of 246.1 M or Total Revenue of 2.5 B can show how well Biomarin Pharmaceutical performed in making a profits. Evaluating Biomarin Pharmaceutical income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Biomarin Pharmaceutical's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Biomarin Pharmaceutical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Biomarin Pharmaceutical is a good buy for the upcoming year.
Biomarin |
About Biomarin Income Statement Analysis
Biomarin Pharmaceutical Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Biomarin Pharmaceutical shareholders. The income statement also shows Biomarin investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Biomarin Pharmaceutical Income Statement Chart
Biomarin Pharmaceutical Income Statement is one of the three primary financial statements used for reporting Biomarin's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Biomarin Pharmaceutical revenue and expense. Biomarin Pharmaceutical Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Biomarin Pharmaceutical's EBIT is very stable compared to the past year. As of the 19th of April 2024, Research Development is likely to grow to about 784.1 M, while Selling General Administrative is likely to drop about 246.1 M. Add Fundamental
Interest Expense
The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.Total Revenue
Total revenue comprises all receipts Biomarin Pharmaceutical generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Biomarin Pharmaceutical minus its cost of goods sold. It is profit before Biomarin Pharmaceutical operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Biomarin Pharmaceutical. It is also known as Biomarin Pharmaceutical overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Biomarin Pharmaceutical's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Biomarin Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.At this time, Biomarin Pharmaceutical's EBIT is very stable compared to the past year. As of the 19th of April 2024, Research Development is likely to grow to about 784.1 M, while Selling General Administrative is likely to drop about 246.1 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 1.4B | 1.6B | 1.8B | 1.9B | Total Revenue | 1.8B | 2.1B | 2.4B | 2.5B |
Biomarin Pharmaceutical income statement Correlations
Click cells to compare fundamentals
Biomarin Pharmaceutical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Biomarin Pharmaceutical income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Depreciation And Amortization | 103.2M | 90.4M | 108.0M | 102.0M | 104.4M | 109.6M | |
Interest Expense | 23.5M | 29.3M | 15.3M | 16.0M | 17.3M | 18.0M | |
Selling General Administrative | 680.9M | 334.3M | 354.3M | 403.7M | 448.9M | 246.1M | |
Total Revenue | 1.7B | 1.9B | 1.8B | 2.1B | 2.4B | 2.5B | |
Gross Profit | 1.3B | 1.3B | 1.4B | 1.6B | 1.8B | 1.9B | |
Other Operating Expenses | 1.8B | 2.0B | 1.9B | 2.1B | 2.3B | 2.4B | |
Operating Income | (125.5M) | (96.3M) | (60.0M) | 57.5M | 157.6M | 165.5M | |
Ebit | (125.5M) | (96.3M) | (60.0M) | 57.5M | 157.6M | 165.5M | |
Research Development | 715.0M | 628.1M | 628.8M | 649.6M | 746.8M | 784.1M | |
Ebitda | (22.2M) | (5.9M) | 48.0M | 159.5M | 262.0M | 275.1M | |
Cost Of Revenue | 359.5M | 524.3M | 470.5M | 483.7M | 577.1M | 605.9M | |
Total Operating Expenses | 1.5B | 1.4B | 1.5B | 1.6B | 1.7B | 1.8B | |
Income Before Tax | (94.8M) | (42.3M) | (75.4M) | 149.6M | 188.6M | 198.0M | |
Total Other Income Expense Net | 30.6M | 53.9M | (15.3M) | 92.0M | 31.0M | 32.5M | |
Net Income | (23.8M) | 854.0M | (64.1M) | 141.6M | 167.6M | 176.0M | |
Income Tax Expense | (71.0M) | (901.4M) | (11.3M) | 8.0M | 20.9M | 22.0M | |
Net Income Applicable To Common Shares | (23.8M) | 859.1M | (64.1M) | 141.6M | 162.8M | 170.9M | |
Net Income From Continuing Ops | (23.8M) | 859.1M | (64.1M) | 141.6M | 147.0M | 154.4M | |
Non Operating Income Net Other | 22.3M | 22.2M | 16.6M | 10.5M | 12.1M | 7.1M | |
Tax Provision | (71.0M) | (901.4M) | (11.3M) | 8.0M | 4.7M | 4.9M | |
Interest Income | 22.7M | 16.6M | 10.5M | 18.0M | 49.0M | 51.5M | |
Net Interest Income | (712K) | (12.7M) | (4.9M) | 2.1M | 34.1M | 35.8M | |
Reconciled Depreciation | 105.3M | 105.2M | 108.0M | 102.0M | 102.1M | 111.0M |
Biomarin Pharmaceutical Investors Sentiment
The influence of Biomarin Pharmaceutical's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Biomarin. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Biomarin Pharmaceutical's public news can be used to forecast risks associated with an investment in Biomarin. The trend in average sentiment can be used to explain how an investor holding Biomarin can time the market purely based on public headlines and social activities around Biomarin Pharmaceutical. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Biomarin Pharmaceutical's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Biomarin Pharmaceutical's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Biomarin Pharmaceutical's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Biomarin Pharmaceutical.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Biomarin Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Biomarin Pharmaceutical's short interest history, or implied volatility extrapolated from Biomarin Pharmaceutical options trading.
Pair Trading with Biomarin Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biomarin Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against Biomarin Stock
0.77 | MRSN | Mersana Therapeutics Downward Rally | PairCorr |
0.73 | EOLS | Evolus Inc Financial Report 14th of May 2024 | PairCorr |
0.62 | INZY | Inozyme PharmaInc Financial Report 14th of May 2024 | PairCorr |
0.58 | JSPRW | Jasper Therapeutics | PairCorr |
0.53 | IOVA | Iovance Biotherapeutics Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to Biomarin Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biomarin Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biomarin Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biomarin Pharmaceutical to buy it.
The correlation of Biomarin Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biomarin Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biomarin Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biomarin Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for Biomarin Stock analysis
When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.98 | Earnings Share 0.87 | Revenue Per Share 12.88 | Quarterly Revenue Growth 0.202 | Return On Assets 0.0163 |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.